PCVX

VaxcyteD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

30%

Probability

Target price

$92.00

+94.1% vs current

Most likely

Base case

45%

Probability

Target price

$63.00

+32.9% vs current

B-

Bear case

25%

Probability

Target price

$38.00

-19.8% vs current

AI sentiment snapshot

Latest data as of 2026-05-14

AI commentary

This T+3 earnings follow-up keeps PCVX in a tentative monitoring view rather than upgrading the thesis. The company source on May 6 confirmed the important points investors wanted to see: full OPUS enrollment, unchanged Q4 2026 OPUS-1 timing, and about $2.74 billion of cash and investments. The update also reinforced how little near-term fundamental de-risking the quarter actually delivered. The May 13 anchor price of $54.25 still suggests a muted-to-negative post-print market read versus late-April trading levels, consistent with investor focus on widening losses and the long wait to decisive data. Analyst-revision visibility remains limited in the packet, and the usable direct operating peer set is narrow, so missing broader post-print target changes should lower confidence rather than be read as positive evidence.

RankAlpha Sentiment Codex - 2026-05-14

Open post-earnings memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Impact

tentative

Confidence

AI events

2026-05-06catalystQ1 update kept the program on schedule but did not materially de-risk the thesisHigh impact

The May 6 earnings update confirmed all three adult OPUS Phase 3 studies are fully enrolled, reiterated OPUS-1 topline data for Q4 2026, and showed cash, cash equivalents and investments of $2.741 billion at March 31, 2026, but it also showed R&D expense of $312.8 million and quarterly net loss of $320.6 million, leaving the setup as funded yet still highly binary. [#8-K-2026-05-06] [#10-Q-2026-05-06]

2026-11-15eventOPUS-1 Phase 3 adult topline data remains the key value inflectionHigh impact

Management reiterated that OPUS-1 topline safety, tolerability and immunogenicity data are expected in Q4 2026, with the study designed as the pivotal noninferiority readout versus current adult PCV standards and as the anchor for the planned BLA path. [#8-K-2026-05-06] [#10-K-2026-02-24]

2027-06-30catalystCash runway and manufacturing buildout support staying power into 2027 milestonesHigh impact

Vaxcyte ended Q1 2026 with about $2.7 billion in cash, cash equivalents and investments after its February equity raise, while continuing commercial-scale manufacturing and fill-finish readiness work; that supports execution into OPUS-2, OPUS-3 and infant readouts, but it does not remove long-duration development, manufacturing and commercialization risk for a company with no approved products. [#8-K-2026-05-06] [#10-Q-2026-05-06] [#10-K-2026-02-24]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-14 • Updated nightlySource: Internal modelMethodology